NYSE Shariah screener · October 2026

Is Quest Diagnostics Incorporated (DGX) Halal?

PASS

Quest Diagnostics Incorporated · NYSE: DGX · Healthcare

The short answer

Yes — Quest Diagnostics (DGX) passes this Shariah stock screen. Its clinical diagnostic testing business (Diagnostic Information Services plus risk assessment services and healthcare IT) has no prohibited lines. At June 30, 2026 interest-bearing debt of $5,642 million ($5,632M long-term plus $10M current portion) is about 21.9% of its ~$25.8 billion market cap (early October 2026), below the ~33% ceiling, with cash of $626 million (~2.4% of market cap). Interest income of $2 million disclosed in the Q1 2026 10-Q is about 0.07% of Q1 2026 net revenues ($2,895 million), far below the 5% non-compliant income ceiling. Zoya covers DGX and currently flags it Shariah-compliant; no Musaffa or ShariaPortfolio rating was found — honestly reported as absent, not invented.

Gate 1 — Business activity: PASS

Quest Diagnostics Incorporated (NYSE: DGX) is a leading U.S. provider of diagnostic information services, operating through two segments: Diagnostic Information Services (DIS) — clinical laboratory testing for physicians, hospitals, health plans, employers, government agencies and individual consumers — and All Other — risk assessment services and healthcare information technology. Services include routine blood and urine testing, advanced and esoteric diagnostics, molecular and genetic testing, anatomic pathology, cancer testing, drug screening and wellness-related assessments, including consumer-initiated tests via questhealth.com. None of the disclosed lines — no alcohol, gambling, pork, conventional banking/insurance, tobacco, cannabis, or adult entertainment — are prohibited lines. Gate 1 passes. Facts only.

Gate 2 — Debt and cash: PASS

At June 30, 2026 the company reported long-term debt of $5,632M plus a current portion of long-term debt of $10M (the $500M of 3.45% senior notes due June 2026 were repaid in full), for total interest-bearing debt of $5,642M, per the Q2 2026 financial tables. Against a market capitalization of about $25.8B (early October 2026 quotes), debt ÷ market cap is about 21.9%, below the ~33% ceiling. Cash and cash equivalents of $626M are about 2.4% of market cap, within the ~33% guideline. Gate 2 passes. Facts only.

Gate 3 — Non-compliant income: PASS

Quest Diagnostics discloses interest income as a separate line in the supplemental cash flow and other data note of its 10-Q filings. For the three months ended March 31, 2026, the note reports interest expense of $65M and interest income of $2M, for interest expense, net of $63M. Against Q1 2026 net revenues of $2,895M, interest income ÷ revenue is about 0.07% — far below the 5% non-compliant income ceiling. (The Q2 2026 earnings statement reports interest expense, net of $63M for the quarter and $126M for the six months ended June 30, 2026, consistent with interest income remaining negligible.) Gate 3 passes. Facts only.

Key figures used

Business: U.S. clinical diagnostic information services — DIS segment (physician, hospital, health-plan, employer, government and consumer testing: routine, advanced, molecular, genetic, anatomic pathology, cancer, drug screening, wellness via questhealth.com); All Other (risk assessment services, healthcare IT)
Interest-bearing debt: $5,642M at Jun 30, 2026 (long-term debt $5,632M + current portion $10M; $500M 3.45% notes due Jun 2026 repaid) — debt ÷ market cap ≈ 21.9%, under the ~33% ceiling; cash $626M ≈ 2.4% of market cap
Market cap: ~$25.8B (early Oct 2026 quotes; DGX ~$231 per share)
Interest income: $2M disclosed in Q1 2026 10-Q supplemental note (vs $65M interest expense) — ≈0.07% of Q1 2026 net revenues $2,895M, far under the 5% ceiling; Q2 2026 interest expense, net $63M quarterly / $126M six months
FY2025: net revenues $11,035M (+11.8%); Q2 2026: net revenues $3,043M (+10.2%); dividend $0.86/quarter raised 7.5%
Zoya covers DGX and currently flags it Shariah-compliant (halal); no Musaffa or ShariaPortfolio rating found — reported as absent, not invented

Frequently asked questions

What does Quest Diagnostics do?

Quest Diagnostics (NYSE: DGX) is a leading U.S. provider of diagnostic information services. It operates two reporting segments: Diagnostic Information Services (DIS), which performs clinical laboratory testing for physicians, hospitals, health plans, employers, government agencies and individual consumers, and All Other, which provides risk assessment services and healthcare information technology solutions. Its services include routine blood and urine testing, advanced and esoteric diagnostics, molecular and genetic testing, anatomic pathology, cancer testing, drug screening and wellness-related assessments, including consumer-initiated tests via questhealth.com. None of the disclosed business lines are prohibited lines, so the business gate passes.

Why does Quest Diagnostics pass this Shariah stock screen?

Quest Diagnostics passes all three gates of this screen. Gate 1: its clinical diagnostic testing business has no prohibited lines (no alcohol, gambling, pork, conventional banking or insurance, tobacco, cannabis, or adult entertainment). Gate 2: at June 30, 2026 interest-bearing debt of $5,642 million (long-term debt $5,632M plus current portion $10M) is about 21.9% of its ~$25.8 billion market cap, below the ~33% ceiling, and cash of $626 million is about 2.4% of market cap. Gate 3: interest income disclosed in the Q1 2026 10-Q notes was $2 million against Q1 2026 net revenues of $2,895 million — about 0.07% of revenue, far below the 5% non-compliant income ceiling. This is a factual screen, not a religious ruling — consult a qualified scholar for personal guidance.

What is Quest Diagnostics' interest-bearing debt ratio?

At June 30, 2026 Quest Diagnostics reported long-term debt of $5,632 million plus a current portion of long-term debt of $10 million (its $500 million of 3.45% senior notes due June 2026 were repaid), for total interest-bearing debt of $5,642 million, per the Q2 2026 financial tables. Against a market capitalization of about $25.8 billion (early October 2026 quotes), debt divided by market cap is about 21.9% — below the ~33% ceiling used in this screen. Cash and cash equivalents of $626 million are about 2.4% of market cap, also within the ~33% guideline. The financial-structure gate passes.

What is Quest Diagnostics' non-compliant income ratio?

Quest Diagnostics discloses interest income as a separate line in the supplemental cash flow and other data note of its 10-Q filings. For the three months ended March 31, 2026, the note reports interest expense of $65 million and interest income of $2 million, for interest expense, net of $63 million. Interest income of $2 million divided by Q1 2026 net revenues of $2,895 million is about 0.07% of revenue — far below the 5% non-compliant income ceiling used in this screen. The income gate passes. (In the Q2 2026 earnings statement the company reports interest expense, net of $63 million for the quarter and $126 million for the six months, consistent with interest income remaining negligible.)

Do Zoya, Musaffa, or ShariaPortfolio cover Quest Diagnostics?

Zoya covers Quest Diagnostics (DGX) on its public screening page and currently flags the stock as Shariah-compliant (halal), based on the company's latest financial reports. No rating or coverage of Quest Diagnostics (NYSE: DGX) was found on Musaffa or ShariaPortfolio — honestly reported as absent, not invented. This page applies the screen directly from the company's filings: the Q1 2026 Form 10-Q (supplemental cash flow and other data note: interest income $2M, filed April 22, 2026), the Q2 2026 earnings release financial tables (June 30, 2026 balance sheet and income statement), and the full-year 2025 results (net revenues $11,035M).

Sources

Screened 2026-10-02 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.

Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).